Pharma Companies Threaten Investment Pullback Amid Germany Drug Pricing Debate sheeba farhat17 Jun 2026 9:02 PM ISTLondon: Global pharmaceutical companies, facing pushback from European capitals on drug pricing, are turning to a playbook that brought them recent...
Pfizer Reviews Germany Investments Amid Concerns Over Drug Pricing Reforms sheeba farhat12 Jun 2026 10:19 PM ISTLondon: Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz,...
Roche Sticks with Major Germany Investment While Eli Lilly, Boehringer Cut Spending sheeba farhat10 Jun 2026 8:35 PM ISTFrankfurt: The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its...
Boehringer's Survodutide Cuts Liver Fat by 63%, Shows Promise Beyond Weight Loss sheeba farhat8 Jun 2026 7:53 PM ISTLondon: Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in a...
Survodutide promising for Obesity with diabetes in Phase 3 trial Dr Kartikeya Kohli4 May 2026 9:45 AM ISTTopline phase 3 trial data in adults with obesity or overweight without type 2 diabetes show promise for survodutide, a dual glucagon and GLP-1...
Boehringer Ingelheim to Set Up AI-Driven Drug Discovery Centre in London sheeba farhat21 April 2026 11:29 PM ISTBengaluru: German drugmaker Boehringer Ingelheim is launching a centre for artificial intelligence and machine learning in London, it said on...
USFDA Grants Fast-Track Nod to Boehringer Ingelheim's Zongertinib for Rare Lung Cancer Kajal Rajput27 Feb 2026 6:52 PM ISTThe approval expands Boehringer's presence in the market for targeted lung cancer therapies, where it will compete with other treatments, including...
Apecotrep Shows Promise in Reducing Proteinuria in Primary FSGS in Phase 2 trial Dr. Kamal Kant Kohli2 Feb 2026 9:45 PM ISTIn a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 weeks in patients with...
Boehringer Ingelheim's Vetmedin Becomes First USFDA-Approved Drug to Delay Heart Failure in Dogs sheeba farhat20 Jan 2026 9:05 PM ISTNew Delhi: Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the...
Boehringer Ingelheim earns USFDA approval for Jascayd tablets for progressive pulmonary fibrosis Ruchika Sharma20 Dec 2025 4:48 PM ISTBoehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD (nerandomilast) tablets for the treatment of...
Boehringer Ingelheim Jascayd receives regulatory approval for progressive pulmonary fibrosis in China Ruchika Sharma11 Dec 2025 11:30 AM ISTIngelheim: Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as the...
Boehringer Ingelheim advances next generation triple-agonist peptide for obesity Ruchika Sharma9 Dec 2025 11:30 AM ISTBoehringer Ingelheim has announced the advancement of BI 3034701, its long-acting potential first-in-class triple-agonist peptide, in development for...
